| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 459 | 2018 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 363 | 2016 |
| Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 216 | 2017 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 173 | 2019 |
| Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy H Beltran, AW Wyatt, EC Chedgy, A Donoghue, M Annala, EW Warner, ... Clinical Cancer Research 23 (22), 6802-6811, 2017 | 80 | 2017 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 69 | 2021 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 68 | 2020 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 66 | 2020 |
| Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ... Clinical Cancer Research 27 (16), 4610-4623, 2021 | 52 | 2021 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8: 444–457. doi: 10.1158/2159-8290 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 50 | |
| DNA repair defects in prostate cancer: impact for screening, prognostication and treatment EW Warner, SM Yip, KN Chi, AW Wyatt BJU international 123 (5), 769-776, 2019 | 39 | 2019 |
| Tissue-and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review K Van der Eecken, J Vanwelkenhuyzen, MP Deek, PT Tran, E Warner, ... European Urology Oncology 4 (6), 914-923, 2021 | 30 | 2021 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8 (4): 444–57 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 24 | |
| Moving toward personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer ECP Chedgy, M Annala, K Beja, EW Warner, ME Gleave, KN Chi, ... Clinical genitourinary cancer 14 (2), e233-e236, 2016 | 20 | 2016 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016; 2: 1598–606 AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... Clin Cancer Res 21, 2315-24, 2015 | 7 | 2015 |
| Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping EW Warner, K Van der Eecken, AJ Murtha, EM Kwan, C Herberts, J Sipola, ... Nature Cancer, 1-17, 2024 | 6 | 2024 |
| A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes EJ Ritch, C Herberts, EW Warner, SWS Ng, EM Kwan, JVW Bacon, ... NPJ Precision Oncology 7 (1), 27, 2023 | 5 | 2023 |
| Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM. S Yip, D Khalaf, WJ Struss, K Sunderland, G Vandekerkhove, EW Warner, ... Journal of Clinical Oncology 36 (6_suppl), 242-242, 2018 | 5 | 2018 |
| Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA. WJ Struss, M Annala, EW Warner, K Beja, G Vandekerkhove, A Wong, ... Journal of Clinical Oncology 35 (6_suppl), 140-140, 2017 | 4 | 2017 |
| Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial T Sumiyoshi, X Wang, EW Warner, A Sboner, M Annala, M Sigouros, ... JNCI: Journal of the National Cancer Institute 116 (1), 115-126, 2024 | 3 | 2024 |
Alexander WyattAssociate Professor, University of British Columbia在 prostatecentre.com 的电子邮件经过验证
